Physician profile
Michael H Liu
NPI 1265887202
$7,537.52
in general payments reported to CMS, 2019-2025
25 companies · $2,496 in 2025
The $2,496 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,401 · 2023: $1,922 · 2024: $1,718 · 2025: $2,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,136.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,652.18 | 2023-2025 | Via Matrix, Novachor, Nushield |
| Abbvie INC. | $1,399.03 | 2022-2025 | |
| Genzyme Corporation | $624.61 | 2022-2025 | |
| Lilly USA, LLC | $509.87 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $489.35 | 2022-2023 | Vtama |
| Incyte Corporation | $422.31 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $407.12 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $294.48 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $248.38 | 2022-2025 | Ilumya, Winlevi, Blu-U |
| Janssen Biotech, INC. | $210.14 | 2022-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $199.40 | 2023-2025 | |
| Amgen INC. | $186.62 | 2022-2023 | Otezla |
| Ucb, INC. | $172.38 | 2022-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $143.32 | 2024-2025 | Nemluvio |
| Leo Pharma INC. | $112.35 | 2023-2025 | Adbry |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $111.78 | 2024 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.00 | 2023-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Kerecis Limited | $62.99 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Botanix Sb INC | $36.96 | 2025 | Sofdra |
| Journey Medical Corporation | $25.05 | 2023 | |
| Arcutis Biotherapeutics, INC. | $23.22 | 2023 | |
| Almirall LLC | $14.09 | 2022 | |
| Allergan, INC. | $11.86 | 2022 | |
| Biofrontera INC. | $9.04 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.